





Patient ID <b>SA00088147</b>	Patient Name <b>TESTING, PATIENT</b>	Birth Date <b>1966-05-26</b>	Gender <b>M</b>	Age <b>50</b>
Order Number <b>SA00088147</b>	Client Order Number <b>SA00088147</b>	Ordering Physician <b>CLIENT, CLIENT</b>	Report Notes <b>G</b>	
Account Information <b>C7035891 SQA Manual 1</b>		Collected <b>26 Mar 2017 00:00</b>		

## Heparin-PF4 IgG Ab (HIT), S

Result Name	Value	Unit	Reference Value	Performing Site
 <b>HIT ELISA</b> 	<b>0.750</b>	OD	<0.400	MCR
Heparin Inhibition	65	%		MCR
 <b>HIT Interpretation</b> 	<b>Positive</b>		Negative	MCR

### HIT Comment

1 MCR

Patient serum has reactivity for antibodies to complexes of heparinoid and platelet factor 4 (H/PF 4 complexes) that is inhibited by high dose heparin. These results suggest possible presence of antibodies implicated in the pathogenesis of immune-mediated heparin induced thrombocytopenia (HIT type II), but do not establish that diagnosis. Clinical correlation is required, and repeat testing may be helpful.

NOTE: As many as 25–50% of surgical patients and 10–20% of medical patients recently exposed to heparin may have evidence of antibodies to H/PF 4 complexes, but only a minority (1–5%) of such heparin exposed patients have evidence of clinical HIT (HIT type II). Although presence of such antibodies may increase the risk of clinical HIT, the magnitude of risk for various patient populations has not been clearly established.

Received: 28 Mar 2017 08:53

Reported: 28 Mar 2017 08:57

### Laboratory Notes

- 1 This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

### Performing Site Legend

Code	Laboratory	Address
MCR	Mayo Clinic Dept. of Lab Med and Pathology	200 First Street SW, Rochester, MN 55905